Catching up on schizophrenia: Natural history and neurobiology

Neuron

Volumn 28, Issue 2, 2000, Pages 325-334

  Lewis, David A ^a   Lieberman, Jeffrey A ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE COURSE; HUMAN; NEUROBIOLOGY; NEUROPATHOLOGY; NEUROPSYCHIATRY; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

EID: 0033638576     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6273(00)00111-2     Document Type: Review

References (96)

1. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics
2. Lamina-specific alteration in the dopamine innervation of the prefrontal cortex in schizophrenic subjects
3. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging
4. Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions
5. Reduced neuronal size in posterior hippocampus of schizophrenic patients
6. Common pattern of cortical pathology in childhood-onset and adult-onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging
7. Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia
8. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
9. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach
10. Epidemiology and natural history of schizophrenia
11. Location of a major vulnerability locus for familial schizophrenia on chromosome 1q21-q22
12. PET and MRI of the thalamus in never-medicated patients with schizophrenia
13. The current status of the dopamine hypothesis of schizophrenia
14. 67 downregulation and psychosis vulnerability
15. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents
16. Dopamine in schizophrenia: A review and reconceptualization
17. Ventricular enlargement in poor-outcome schizophrenia
18. Comparison of the effects of clozapine, risperidone, olanzapine on ketamine-induced alterations in regional brain metabolism
19. Effect of COMT108/158 Met genotype on frontal lobe function and risk for schizophrenia
20. D2 dopamine receptors in neuroleptic-naive schizophrenic patients
21. Brain anatomic magnetic resonance imaging in childhood-onset schizophrenia
22. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia
23. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter
24. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia: Regional and diagnostic specificity
25. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia
26. Working memory dysfunction in schizophrenia
27. Functional and anatomical aspects of prefrontal pathology in schizophrenia
28. Cortical abnormalities in schizophrenia identified by structural magnetic resonance imaging
29. What are the functional consequences of neurocognitive deficits in schizophrenia?
30. A follow-up magnetic resonance imaging study of schizophrenia
31. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia
32. Causes and consequences of the gender difference in age of onset of schizophrenia
33. The neuropathology of schizophrenia: A critical review of the data and their interpretation
34. Cognitive decline in late-life schizophrenia: A longitudinal study of geriatric, chronically hospitalized patients
35. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia
36. Activity-dependent regulation of GABA expression in the visual cortex of adult monkeys
37. Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness
38. Cortical BCL-2 protein expression and apoptotic regulation in schizophrenia
39. Recent advances in the phencyclidine model of schizophrenia
40. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia
41. Drug therapy. Schizophrenia
42. The early origins of schizophrenia
43. Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia
44. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophenia: A possible neurochemical basis for 'hypofrontality'
45. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia
46. Mechanisms of action of atypical antipsychotic drugs: A critical analysis
47. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
48. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia
49. The role of endogenous sensitization in the pathophysiology of schizophrenia
50. Single photon emission computerized tomography imaging of amphetamine-induced release in drug-free schizophrenic subjects
51. Increased dopamine transmission in schizophrenia: Relationship to illness phase
52. Development of the prefrontal cortex during adolescence: Insights into vulnerable neural circuits in schizophrenia
53. Is there a neuropathology of schizophrenia?
54. Is schizophrenia a neurodegenerative disorder?
55. Time course and biological correlates of treatment response in first episode schizophrenia
56. Psychobiologic correlates of treatment response in schizophrenia
57. Neurochemical sensitization in the pathophysiology of schizophrenia: Deficits and dysfunction in neuronal regulation and plasticity
58. Obstetric complications and familial morbid risk of psychiatric disorders
59. MRI anatomy of schizophrenia
60. Early detection and intervention in schizophrenia research
61. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex
62. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats
63. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia
64. Effects of family history and place and season of birth on the risk of schizophrenia
65. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET
66. Glutamate receptor dysfunction and schizophrenia
67. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics
68. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia
69. Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects
70. Subnucleus-specific loss of neurons in medial thalamus of schizophrenics
71. Volumetric evaluation of the thalamus in schizophrenic male patients using magnetic resonance imaging
72. Search for schizophrenia vulnerability genes
73. Schizophrenia as a developmental disorder of the cerebral cortex
74. Neuronal and glial somal size in the prefrontal cortex: A postmortem morphometric study of schizophrenia and Huntington disease
75. Progressive cortical change during adolescence in childhood-onset schizophrenia: A longitudinal magnetic resonance imaging study
76. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder
77. Predictors of relapse following from a first episode of schizophrenia or schizoaffective disorder
78. The reduced neuropil hypothesis: A circuit based model of schizophrenia
79. The evaluation and treatment of first episode psychoses
80. Gender differences in onset of illness, treatment response, course, and biological indexes in first-episode schizophrenic patients
81. Cerebral blood flow activation and functional lesions in schizophrenia
82. Seasonality of births in schizophrenia and bipolar disorder: A review of the literature
83. Schizophrenia: Genes and environment
84. 67 mRNA expression in a subset of prefrontal cortical GABA neurons in subjects with schizophrenia
85. Prediction of adult onset schizophrenia from childhood home movies
86. Cell biology of the hippocampal formation in schizophrenia
87. Cognitive dysfunction in schizophrenia
88. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia
89. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: A search for common ground
90. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics
91. Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia
92. The prodromal phase of first-episode schizophrenia: Past and current conceptualizations
93. Size, shape, and orientation of neurons in the left and right hippocampus: Investigation of normal asymmetries and alterations in schizophrenia